ClinicalTrials.gg
Not yet recruitingNCT07745647Updated Nov 5, 2026

Voll Non-Degradable Shoulder Spacer FIH Study

An interventional study of Voll Non-Degradable Shoulder Spacer in Massive Rotator Cuff Tears and Massive Rotator Cuff Tear, sponsored by Voll Medical Technologies Ltd.. Not yet recruiting at 1 site in Israel. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Voll Medical Technologies Ltd. · Not applicable, Interventional, and Treatment

How we know

Updated Nov 5, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Study summary

The Voll Non-Degradable Shoulder Spacer First-in-Human study aims to evaluate the initial safety, effectiveness, and clinical outcomes of a non-degradable shoulder spacer in over 50 years old patients with symptomatic massive rotator cuff tears (MRCT).

02

Conditions studied

  • Massive Rotator Cuff Tears
  • Massive Rotator Cuff Tear

Browse trials for

03

In context

Rotator Cuff Injuries

632 studies on the registry are indexed under Rotator Cuff Injuries; 157 are open to participants now.

This study's planned enrollment of 10 is below the median of 60 across 456 interventional studies indexed under Rotator Cuff Injuries.

Browse Rotator Cuff Injuries studies →

Lead sponsor

Voll Medical Technologies Ltd. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Full thickness MRCT.
  • Male or female patients ≥ fifty (50) years of age, in general good health, independent, and can comply with all post-operative evaluations and visits.

Exclusion criteria

Exclusion Criteria:

  • Documented evidence of a history of drug/alcohol abuse within 1 year of enrollment.
  • Concurrent participation in any other clinical study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Voll Non-Degradable Shoulder Spacer

    Voll Non-Degradable Shoulder Spacer

    Device: Voll Non-Degradable Shoulder Spacer

Interventions

  • DeviceVoll Non-Degradable Shoulder Spacer

    Voll Non-Degradable Shoulder Spacer

06

What researchers measure

Primary outcomes

  1. Device-related Serious Adverse Events

    Incidence of device-related serious adverse events (DRSAEs) related to the spacer.

    Time frame: Up to 12 months post-implantation

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Sep 2027, 9 months later.

Of 252 interventional studies with no phase under Rotator Cuff Injuries, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 9 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2026
First posted
Aug 4, 2026
StartEst.
Dec 2026was Sep 2026
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Dec 2026
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Start date Sep 2026→Dec 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07745647
Lead sponsor
Voll Medical Technologies Ltd.
Responsible party
Sponsor
First posted
Aug 4, 2026
Start date
Dec 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Sep 2028 (estimated)
Last update
Nov 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion